Shirish Gadgeel, MD, and Benjamin Levy, MD, discuss recent updates in 2023 on antibody-drug conjugates for treating patients with advanced NSCLC as well as their clinical implications.
January 18th 2024
Benjamin Levy, MD, discusses the role of molecular testing in patients with advanced NSCLC.
January 22nd 2024
Benjamin Levy, MD, reviews clinical data on T-DXd in HER2 mutated advanced NSCLC and their practical implications.
January 26th 2024
Benjamin Levy, MD, reviews clinical data on Dato-DXd in patients with advanced NSCLC and their practical implications.
February 6th 2024
Dr. Shirish Gadgeel discusses recent EVOKE-2 trial results showing promising response rates with sacituzumab govitecan combined with pembrolizumab for metastatic non-small cell lung cancer.
February 9th 2024
Dr. Gadgeel reviews the HERTHENA-Lung01 trial results of the HER3 targeting antibody drug conjugate patritumab deruxtecan in EGFR-positive non-small cell lung cancer.
February 12th 2024
Dr. Shirish Gadgeel discusses the activity of antibody drug conjugates against brain metastases in non-small cell lung cancer based on emerging data, suggesting superiority over chemotherapy.
February 26th 2024
Benjamin Philip Levy, MD, details how antibody-drug conjugates are shifting the HER2-mutated non–small cell lung cancer treatment paradigm.
April 12th 2024
Shirish M, Gadgeel, MD, highlights key treatment advances achieved with antibody-drug conjugates in non–small cell lung cancer.